CD274 and neoplasm: With regard to the adopted drug, ORR was significantly higher in patients with PD-L1 positive tumor in comparison to PD-L1 negative tumor for nivolumab and pembrolizumab, with an absolute difference of 16.4% (95% CI 10.0–22.7) and 19.5% (95% CI 8.1–27.8) respectively (Fig 3).